linjc16/ctgov huggingface dataset:
Fast Track Rehabilitation Following Video-assisted Lung Segmentectomy

Study Overview
=================
Brief Summary
-----------------
Aim of this prospective randomized study is to assess the safety and efficacy of video-assisted lung segmentectomy (Group B) comparing with mini muscle-sparing thoracotomy (group A) during diagnostic process for pulmonary nodules.

Conditions
-----------------
Multiple Pulmonary Nodules

Intervention / Treatment
-----------------
* Other: VATS
* Procedure: Mini thoracotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with undiagnosed multiple pulmonary nodules Exclusion Criteria: Centrally located lesions previous thoracotomy extensive lung consolidation, and inability to achieve one lung ventilation

Ages Eligible for Study
-----------------
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Video-assisted lung segmentectomy<br>Patients undergoing VATS segmentectomy | Other: VATS<br>* Video-assisted lung segmentectomy<br>|
| Other: Mini thoracotomy<br>Patients undergoing lung segmentectomy through a mini thoracotomy | Procedure: Mini thoracotomy<br>* Mini muscle sparing thoracotomy for lung segmentectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospital stay |  | Participants will be followed till home discharge, an average of 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative morbidity |  | Participants will be followed till home discharge, an average of 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung, Nodule, Rehabilitation, VATS, Thoracotomy
Levobupivacaine During Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy.

Official Title
-----------------
Effects of Intraperitoneal Levobupivacaine on Pain After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-Blinded Study

Conditions
-----------------
Cholelithiasis, Pain

Intervention / Treatment
-----------------
* Drug: levobupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cholelithiasis chronic cholecystitis Exclusion Criteria: hypersensitivity to local anesthetics acute cholecystitis morbid obesity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopic cholecystectomy
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the Punctal Plug Delivery System is safe and effective in controlling intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Official Title
-----------------
An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG)

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Latanoprost-PPDS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 yrs with ocular hypertension or open-angle glaucoma Subjects who have a best-corrected visual acuity of 20/100 or better. Exclusion Criteria: Subjects who wear contact lenses. Uncontrolled medical conditions Subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic topical medications. Subjects who have a history of chronic or recurrent inflammatory eye disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Punctal plug<br> | Drug: Latanoprost-PPDS<br>* Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP change from baseline |  | 6 weeks |
Health Related QOL, Depression and Lifestyle Changes in Insulin Resistant Adolescents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess adolescents with Insulin Resistance Syndrome for quality of life and altered health related issues.

Detailed Description
-----------------
Matched historical control study designed to examine outcomes on insulin resistant adolescents who were treated in the Insulin Resistance Syndrome Clinic at Children's Mercy Hospital in the past year. New patients will be screened at baseline, 4 and 12 months to evaluate if there is improvement in the BMI Z-score, HgA1c, lipid profile or waist circumference when depression and/or altered health related quality of life are identified and treated in this population.

Official Title
-----------------
Health-related Quality of Life, Depression and the Impact on Successful Incorporation of Lifestyle Changes in Insulin Resistant Adolescents as Evidenced by Changes in BMI, Waist Circumference and Metabolic Parameters

Conditions
-----------------
Insulin Resistance, Depression

Intervention / Treatment
-----------------
* Behavioral: Health-Related Quality of Life instrument
* Behavioral: Depression Scale for Children (CES-DC)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 11-17 years of age who are seen in the Insulin Resistance Clinic for the first time Historical control: Patients 11-19 years of age seen in the Insulin Resistance Clinic during the prior four months Exclusion Criteria: Co-morbid syndrome (Downs, Turner's, Prader Willi etc) Diagnosis of Type 2 Diabetes Taking Metformin before the initial visit Taking medication for or diagnosis of a psychiatric condition prior to initial visit Developmentally delayed

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome|
|Behavioral: Depression Scale for Children (CES-DC)|questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Health-Related Quality of Life
Ultrasound Elastography Application in Cesarean Section Scar Defect

Study Overview
=================
Brief Summary
-----------------
Cesarean Section Scar Defect(CSD) is one of the complications after cesarean section. CSD will cause many long term complications, such as abnormal uterine bleeding, infertility, uterine scar pregnancy and uterine rupture. Transvaginal ultrasound was used to detect uterine scar defects commonly. Ultrasound elastography is a modern imaging technique that has developed rapidly in recent years. Thus, this study intend to investigate the application of Ultrasound Elastography in Cesarean Section Scar Defect.

Official Title
-----------------
Ultrasound Elastography Application in the Assessment of Cesarean Section Scar Defect.

Conditions
-----------------
Cesarean Section; Dehiscence

Intervention / Treatment
-----------------
* Other: Ultrasound Elastography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clearly diagnosed with CSD No serious medical problems (important viscera function in the normal range). uterine fibroids no more than 5cm Sign the informed consent. Exclusion Criteria: Indefinite diagnosis. Malignant tumors. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs). Pregnant. Mental diseases. Unwilling to comply with the research plan.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ultrasound Elastography<br>Patients will be examined by ultrasound elastography. | Other: Ultrasound Elastography<br>* Patients will be examined by ultrasound elastography.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| thickness of the remaining muscular layer | The thickness of the remaining muscular layer is measured by ultrasound | 4 weeks before vaginal repair of CSD | 
| thickness of the remaining muscular layer | The thickness of the remaining muscular layer is measured by ultrasound | 12 weeks after vaginal repair of CSD | 
| strain ratio (SR) | the ratio of mean strain in the lesion to the adjacent background tissue | 4 weeks before vaginal repair of CSD | 
| strain ratio (SR) | the ratio of mean strain in the lesion to the adjacent background tissue | 12 weeks after vaginal repair of CSD |
A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
This study's primary goals are to test the safety and effectiveness of Tobramycin for Inhalation (TOBIr) in cystic fibrosis (CF) patients who are between 6 months and 6 years of age. This drug is an antibiotic that is inhaled into the lungs by the patient. It has already been studied and approved by the FDA for treatment of CF patients 6 years and older. Lung fluid will be examined for bacteria before and after the 28-day treatment. The amount of bacteria before and after treatment will be compared. This will indicate whether the antibiotic was effective in killing bacteria in the lungs. Once treatment begins, patients will be monitored every 2 weeks throughout the study (5 exams in 56 days). Half of the patients will receive TOBIr, half will receive a placebo (a substance that looks like TOBIr but contains no medication).

Official Title
-----------------
A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Drug: Tobramycin for Inhalation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age at least 6 months and less than 6 years Diagnosis of cystic fibrosis with 2 clinical features consistent with CF and confirmed by either sweat chloride >= 60 mEq/L (by quantitative pilocarpine iontophoresis) or by genotype with 2 identifiable mutations consistent with CF. One throat or sputum microbiology culture positive for Pseudomonas aeruginosa (Pa) within 2 weeks to 12 months prior to screening. Informed consent by parent or legal guardian. Exclusion Criteria: History of adverse reaction to anesthesia or sedation. History of aminoglycoside hypersensitivity. History of unresolved anemia (hematocrit < 30%) or thrombocytopenia (platelet count < 100,000/mm3). History of hemoptysis with 30 days prior to screening. History of abnormal renal function (serum creatinine > 1.5 times the upper limit of normal for age). History of clinically documented chronic hearing loss. Administration of any investigational drug within 30 days prior to screening.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tobramycin for Inhalation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cystic Fibrosis
Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations (on and off states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.

Official Title
-----------------
Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: Ropinirole Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must give written informed consent prior to any specific study procedures. Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study. Age greater than or equal to 25 years. Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day). Stable dose of all medications for 4 weeks. Exclusion Criteria: Current hallucinations. History of disabling hallucinations or hallucinations in past requiring treatment. Troublesome edema (swelling). Unstable depression. Female who is pregnant or lactating. Use of an investigational drug with in the last 30 days. Other inclusion or exclusion criteria to be evaluated by the physician.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ropinirole Hydrochloride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ropinirole, Parkinson's disease, dopamine agonist
Maintaining the Head Extension by an Assistant Decreases Dental Contact

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the head extension by an assistant decreases dental contact between laryngoscope blade and maxillary incisors during direct laryngoscopy

Official Title
-----------------
Maintaining the Head Extension by an Assistant Decreases Dental Contact Between Laryngoscope Blade and Maxillary Incisors During Direct Laryngoscopy

Conditions
-----------------
Dental Contact During Direct Laryngoscopy

Intervention / Treatment
-----------------
* Procedure: with assistant
* Procedure: without assistant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing surgery that requires general anesthesia Exclusion Criteria: disease or injury of cervical spine dentoalveolar injury history of difficult intubation anatomical anomaly of face or airway

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: with assistant<br>head extension by an assistant during direct laryngoscopy | Procedure: with assistant<br>* head extension by an assistant during direct laryngoscopy<br>|
| Active Comparator: without assistant<br>without the help of an assistant during direct laryngoscopy | Procedure: without assistant<br>* without head extension by an assistant during direct laryngoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dental contact | dental contact between laryngoscope blade and maxillary incisors | up to 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| teeth distance | teeth distance between laryngoscope blade and maxillary incisors | up to 10 minutes |
ADVATE Post Authorization Safety Surveillance

Study Overview
=================
Brief Summary
-----------------
The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.

Official Title
-----------------
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study

Conditions
-----------------
Hemophilia A

Intervention / Treatment
-----------------
* Drug: rAHF-PFM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%) Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method) Subject has been prescribed ADVATE by their treating physician Subject may be of any age Subject or parent/legally authorized representative has provided written informed consent Exclusion Criteria: None
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rAHF-PFM|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty

Study Overview
=================
Brief Summary
-----------------
Mitral insufficiency (MI) accounts for 24% of adult valvulopathies and affects 7% of subjects older than 75 years. They are the second leading cause of valvulopathy in Europe. The most common etiology is the associated valvular prolapse. Mitral surgery remains the reference treatment for symptomatic MI. The success of this procedure depends on the mitral valve geometry and the location of the prolapse. The site of the prolapse, whether monovalvular, localized to the posterior or anterior leaflet, or bivalvular, influences the possibilities and probably the long-term results of the plasty.

Official Title
-----------------
Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty

Conditions
-----------------
Mitral Valve Prolapse, Mitral Plasty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients operated between 1988 and 2011 Presence of a valvular prolapse diagnosed by echocardiography Possibility of a complete clinical evaluation at the time of the initial echocardiography Exclusion Criteria: Ischemic MI (including papillary muscle rupture) Presence of significant aortic valvulopathy, mitral valvular stenosis or congenital disease History of cardiac surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival defines as the time between the date of surgery and the death or date of the last news |  | 6 months |